Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Travere Therapeutics, Inc. (TVTX) had Normalized Income after Taxes of $-12.76M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$114.45M |
|
$-12.76M |
|
$1.52M |
|
$112.93M |
|
$127.10M |
|
$-12.65M |
|
$-0.09M |
|
$-12.73M |
|
$-12.73M |
|
$-12.76M |
|
$-12.76M |
|
$-12.76M |
|
|
Normalized Income after Taxes |
$-12.76M |
$-12.65M |
|
$1.37M |
|
88.95M |
|
88.95M |
|
$-0.14 |
|
$-0.14 |
|
| Balance Sheet Financials | |
$379.57M |
|
$4.56M |
|
$175.74M |
|
$555.31M |
|
$189.54M |
|
$311.02M |
|
$333.02M |
|
$522.56M |
|
$32.75M |
|
$-72.86M |
|
$32.75M |
|
89.10M |
|
| Cash Flow Statement Financials | |
$-37.21M |
|
$46.14M |
|
$5.19M |
|
$58.53M |
|
$75.15M |
|
$16.62M |
|
$22.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.00 |
|
-- |
|
-- |
|
0.90 |
|
11.60 |
|
98.67% |
|
-11.05% |
|
-11.05% |
|
-- |
|
-11.13% |
|
-11.14% |
|
$-37.45M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.37 |
|
2.96 |
|
30.45 |
|
-38.95% |
|
17.51% |
|
-2.30% |
|
-3.71% |
|
$0.37 |
|
$-0.42 |
|
$-0.42 |
|